AMENDMENTS TO THE SPECIFICATION:

Please amend the following passage of the specification appearing on p. 57, ln. 20-29:

Such formats include, but are not limited to, Protein Data Bank ("PDB") format (Research Collaboratory for Structural Bioinformatics~~; http://www.rcsb.org/pdb/docs/format/pdbguide2.2/guide2.2_frame.html~~); Cambridge Crystallographic Data Centre format ~~(http://www.ccdc.cam.ac.uk/support/csd_doc/volume3/z323.html)~~; Structure-data ("SD") file format (MDL Information Systems, Inc.; Dalby et al., 1992, J. Chem. Inf. Comp. Sci. 32:244-255), and line-notation, e.g., as used in SMILES (Weininger, 1988, J. Chem. Inf. Comp. Sci. 28:31-36). Methods of converting between various formats read by different computer software will be readily apparent to those of skill in the art, e.g., BABEL (v. 1.06, Walters & Stahl, ©1992, 1993, 1994~~; http://www.brunel.ac.uk/departments/chem/babel.htm~~.)

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): An isolated compound which inhibits pilus assembly**, or a pharmaceutically-acceptable salt thereof**, said compound comprising a mimic of a chaperone G1 beta-strand or a mimic of an amino terminal motif of a pilus subunit, wherein the mimic is a 10 to 20 residue peptide, having an amino terminus and a carboxy terminus, according to formula (I):

~~(I)~~ Z_1~Z_2–X_1–X_2–X_3–X_4–X_5–X_6–X_7–X_8–X_9–X_{10}–Z_3~Z_4 **(I)** ~~or a pharmaceutically-acceptable salt thereof,~~

wherein:

Z_1 is the amino terminus of the mimic peptide, Z_1 having the formula R-C(O)-NR- or RRN-;

Z_2 is (i) a first peptide sequence consisting of 1 to 5 amino acid residues or (ii) a bond connecting Z_1 to X_1;